Recent innovations in oral contraception

Seminars in Reproductive Medicine

Volumn 28, Issue 2, 2010, Pages 140-146

  Cremer, Miriam ^a   Phan Weston, Scarlett ^b   Jacobs, Adam ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b SMITH COLLEGE   (United States)

Author keywords

24 4; 84 7; Drospirenone; Extended regimen; Lybrel

Indexed keywords

DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; LEVONORGESTREL; PLACEBO;

ACNE VULGARIS; CLINICAL TRIAL; ENDOMETRIUM; HIRSUTISM; HUMAN; HYPERKALEMIA; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; ORAL CONTRACEPTION; PREMENSTRUAL DYSPHORIC DISORDER; REVIEW; THROMBOEMBOLISM;

ACNE VULGARIS; ANDROSTENES; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; ENDOMETRIAL HYPERPLASIA; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; HYPERKALEMIA; LEVONORGESTREL; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; OVULATION; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; UTERINE HEMORRHAGE;

EID: 77951120392     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1248139     Document Type: Review

References (41)

1. Mosher W D., Martinez G M., Chandra A, Abma J C., Willson S J. Use of contraception and use of family planning services in the United States: 19822002. Adv Data 2004 (350) 1-36
2. Loudon N B., Foxwell M, Potts D M., Guild A L., Short R V. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 1977 2 (6085) 487-490
3. Edelman A, Gallo M F., Nichols M D., Jensen J T., Schulz K F., Grimes D A. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006 21 (3) 573-578 (Pubitemid 43372958)
4. Trussell J. Contraceptive efficacy In: Hatcher RA, Trussell J, Nelson AL, Willard Cates J, Stewart F, Kowal D Contraceptive Technology 19th ed. New York, NY Ardent Media 2007
5. Facts on Contraceptive Use. 2008. Guttmacher Institute. Available at: http://.www.guttmacher.org/pubs/fb-contr-use.html Accessed September 15, 2009
6. Baerwald A R., Pierson R A. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can 2004 26 (1) 19-24
7. Killick S R., Fitzgerald C, Davis A. Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 1998 179 (1) S18-S24
8. Schlaff W D., Lynch A M., Hughes H D., Cedars M I., Smith D L. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 2004 190 (4) 943-951
9. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999 72 (1) 115-120 (Pubitemid 29300271)
10. Nakajima S T., Archer D F., Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007 75 (1) 16-22 (Pubitemid 44854856)
11. Bachmann G, Sulak P J., Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004 70 (3) 191-198 (Pubitemid 39119980)
12. Rosenberg M J., Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999 60 (6) 321-329 (Pubitemid 30133220)
13. Sulak P J., Carl J, Gopalakrishnan I, Coffee A, Kuehl T J. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 2004 70 (4) 281-287 (Pubitemid 39286762)
14. Brown C S., Ling F W., Andersen R N., Farmer R G., Arheart K L. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994 84 (5) 779-786
15. Hahn P M., Van Vugt D A., Reid R L. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995 20 (2) 193-209 (Pubitemid 24366200)
16. Yonkers K A., Brown C, Pearlstein T B., Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005 106 (3) 492-501 (Pubitemid 41208780)
17. Pearlstein T B., Bachmann G A., Zacur H A., Yonkers K A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005 72 (6) 414-421 (Pubitemid 41676830)
18. Yaz drospirenone and ethinyl estradiol tablets. Prescribing information. Wayne, NJ Bayer HealthCare Pharmaceuticals Inc.; 2007 Available at: http://berlex.bayerhealthcare.com/html/products/pops/fhc9.html?WT.mc-id=www. berlex.com Accessed September 2009
19. Maloney J M., Dietze P Jr, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008 112 (4) 773-781
20. Lucky A W., Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008 82 (2) 143-150
21. Anderson F D., Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003 68 (2) 89-96
22. Anderson F D., Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006 195 (1) 92-96
23. Anderson F D., Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006 73 (3) 229-234
24. Kaunitz A M., Portman D J., Hait H, Reape K Z. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Contraception 2009 79 (5) 350-355
25. Anderson F D., Feldman R, Reape K Z. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception 2008 77 (2) 91-96
26. Anderson F D., Hait H, Hsiu J, Thompson-Graves A L., Wilborn W H., Williams R F. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005 71 (1) 55-59
27. den Tonkelaar I, Oddens B J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999 59 (6) 357-362
28. Andrist L C., Arias R D., Nucatola D et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004 70 (5) 359-363 (Pubitemid 39422511)
29. Lybrel package insert. 2007. Wyeth. Available at: http://www.lybrel.com/ patient-package-insert Accessed September 15, 2009
30. Archer D F., Jensen J T., Johnson J V., Borisute H, Grubb G S., Constantine G D. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006 74 (6) 439-445 (Pubitemid 46037535)
31. Teichmann A, Emerich C, Greven D et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception 2009 80 (6) 504-511
32. Miller L, Hughes J P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003 101 (4) 653-661 (Pubitemid 36390051)
33. Mishell D R. Jr. Family planning In: Katz VL, Lobo RA, Lentz G, Gershenson D Comprehensive Gynecology. 5th ed. St. Louis, MO Mosby 2007 275-325
34. Mishell D R. Jr. YAZ and the novel progestin drospirenone. J Reprod Med 2008 53 (9, suppl) 721-728
35. Loughlin J, Seeger J D., Eng P M. et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 2008 78 (5) 377-383
36. Heinemann L A., Lewis M A., Assmann A, Thiel C. Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002 65 (3) 207-214
37. Dinger J C., Heinemann L A., Khl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007 75 (5) 344-354
38. Seeger J D., Loughlin J, Eng P M., Clifford C R., Cutone J, Walker A M. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007 110 (3) 587-593
39. Batukan C, Muderris I I., Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007 23 (1) 38-44
40. Gregoriou O, Papadias K, Konidaris S et al. Treatment of hirsutism with combined pill containing drospirenone. Gynecol Endocrinol 2008 24 (4) 220-223
41. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007 12 (1) 30-35